Igc pharma expands calma trial with addition of baycare health system in florida

Potomac, maryland / access newswire / march 17, 2025 / igc pharma, inc. (nyse american:igc) ("igc pharma" or the "company") today announced the addition of a new trial site at baycare's st. anthony's hospital in st. petersburg, florida as part of its ongoing phase 2 calma trial evaluating igc-ad1, the company's lead therapeutic candidate, for the treatment of agitation in alzheimer's dementia. igc-ad1 is a combination therapy designed to address agitation in alzheimer's disease.
IGC Ratings Summary
IGC Quant Ranking